EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Medical Advancements in Benign Prostatic Hyperplasia Treatments

Vishnuvardhan Ganesan, Deepak Agarwal

Current Urology Reports · 2024

DOI: 10.1007/s11934-024-01199-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Urology Reports, 2024. Verfasst von Vishnuvardhan Ganesan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Minnesota, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Erectile Dysfunction, Lower Urinary Tract Symptoms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: This review aims to identify and summarize the current literature on the most recent therapeutic agents and combination strategies for the medical management of lower urinary tract symptoms resulting from benign prostatic hyperplasia. RECENT FINDINGS: The latest advancements in BPH therapy have been in combination strategies. Alpha blockers continue to be the mainstay of treatment, but research is exploring the synergistic benefits of combining them with 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and beta-3 agonists. The alpha-blocker + 5-ARI combination remains ideal for enlarged, significantly reducing clinical progression risk compared to monotherapy. Alpha-blocker + PDE5 inhibitor combinations appear safe and potentially beneficial for men with concomitant erectile dysfunction; sildenafil might hold an edge over tadalafil based on limited data. Beta-3 agonists show synergistic effects with alpha blockers for residual storage symptoms, offering similar efficacy to anticholinergics but with a better side effect profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaErectile DysfunctionLower Urinary Tract SymptomsMaleHumansDrug Therapy, CombinationPhosphodiesterase 5 InhibitorsTadalafilAdrenergic alpha-AntagonistsTreatment Outcome

Stichwörter der Autor:innen

5 Alpha reductase inhibitorsAlpha blockersBenign prostatic hyperplasiaBeta-3 agonistsMedical therapyPhosphodiesterase 5 inhibitors

Substanzen

Phosphodiesterase 5 InhibitorsTadalafilAdrenergic alpha-Antagonists

Autor:innen und Institutionen

  • Department of Urology, University of Minnesota, Minneapolis, MN, USA.
  • Department of Urology, University of Minnesota, Minneapolis, MN, USA. dagarwal@umn.edu.

Zitieren

APA

Ganesan, V., & Agarwal, D. (2024). Medical Advancements in Benign Prostatic Hyperplasia Treatments. Current Urology Reports. https://doi.org/10.1007/s11934-024-01199-4

Vancouver

Ganesan V, Agarwal D. Medical Advancements in Benign Prostatic Hyperplasia Treatments. Current Urology Reports. 2024. doi:10.1007/s11934-024-01199-4

BibTeX
@article{Ganesan2024,
  author = {Ganesan, Vishnuvardhan and Agarwal, Deepak},
  title = {Medical Advancements in Benign Prostatic Hyperplasia Treatments},
  journal = {Current Urology Reports},
  year = {2024},
  doi = {10.1007/s11934-024-01199-4}
}
Kostenlos starten →